Individualized brain stimulation improves walking
- Trial ID
- NCT07570212
- Official Title
- Exploration of the Efficacy of Individualized Transcranial Magnetic Stimulation in the Treatment of Parkinsonian Disorders
- Goal
- Individualized brain stimulation improves walking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Peking University First Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 50 participants
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Interventions
- TMS
Summary For Families
The trial tests whether individualized transcranial magnetic stimulation can reduce motor and related symptoms in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy by targeting the specific brain circuits that are malfunctioning. It delivers focused magnetic pulses guided by each person’s EEG and MRI to change abnormal neural excitability; it does not replace levodopa, but by normalizing circuit activity it may improve response to existing medications and reduce symptoms. The team is enrolling adults 30 to 80 with clinically established or probable PD, MSA, or PSP at moderate stages (PD H‑Y 2,4; MSA UMSARS Part IV 1,4; PSP mRS 2,4) who can consent and follow study procedures. People with metallic implants or pacemakers, a history of epilepsy, MRI or EEG contraindications, current TMS or similar therapies, unstable medical conditions, or certain psychiatric issues are not eligible.
Locations
- Peking University First Hospital, Beijing, Beijing Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying TMS. The trial tests whether individualized transcranial magnetic stimulation can reduce motor and related symptoms in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy by targeting the specific brain circuits that are malfunctioning. It delivers focused magnetic pulses guided by each person’s EEG and MRI to change abnormal neural excitability; it does not replace levodopa, but by normalizing circuit activity it may improve response to existing medications and reduce symptoms. The team is enrolling adults 30 to 80 with clinically established or probable PD, MSA, or PSP at moderate stages (PD H‑Y 2,4; MSA UMSARS Part IV 1,4; PSP mRS 2,4) who can consent and follow study procedures. People with metallic implants or pacemakers, a history of epilepsy, MRI or EEG contraindications, current TMS or similar therapies, unstable medical conditions, or certain psychiatric issues are not eligible.
- Who can participate?
- Participants must be between 30 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 9 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.